Concordance Between Clinician-Reported and Patient-Reported Outcomes of Eyebrow and Eyelash Hair Loss in Patients With Severe Alopecia Areata: Results From BRAVE-AA1 and BRAVE-AA2 Studies

    Arash Mostaghimi, Justin Ko, Antonellá Tosti … Andreas Wollenberg
    Studysummary This study evaluated the agreement between clinician and patient assessments of eyebrow and eyelash hair loss severity in adults with severe alopecia areata, using data from two phase 3 studies over 52 weeks.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Read the full study on doi.org →
    Discuss this study in the Community →

    Research cited in this study 3

    1. The Invisible Impact Of A Visible Disease: Psychosocial Impact Of Alopecia Areata Dermatology and Therapy · 2023
    2. Efficacy and Safety of Baricitinib in Patients with Severe Alopecia Areata Over 52 Weeks in Phase III Trials American Journal of Clinical Dermatology · 2023
    3. Development of Clinician-Reported Outcome and Patient-Reported Outcome Measures for Eyebrow, Eyelash, and Nail Assessment in Alopecia Areata American Journal of Clinical Dermatology · 2020

    Related research 3

    1. Baseline Distribution of Eyebrow and Eyelash Loss by Severity of Scalp Hair Loss in Phase 3 Trials of Baricitinib for Alopecia Areata Journal of The American Academy of Dermatology · 2023
    2. Baricitinib Results in Eyebrow and Eyelash Growth in Patients With Alopecia Areata Who Do Not Achieve 20% or Less Scalp Hair Loss Journal of The American Academy of Dermatology · 2022
    3. Review of Representative Trichoscopic Findings in Androgenetic and Alopecia Areata Patients Visiting Dermatology Outpatient Clinic at University Hospital 대한피부과학회지 · 2016